Drug Profile


Alternative Names: ACR343

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Carlsson Research AB
  • Developer Saniona
  • Class Antiparkinsonians; Antipsychotics; Fluorobenzenes; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Gilles de la Tourette's syndrome; Parkinson's disease

Most Recent Events

  • 31 May 2016 Saniona acquires ACR 343 from NeuroSearch
  • 31 May 2016 Phase-I clinical trials in Gilles de la Tourette's syndrome in Sweden (PO)
  • 31 May 2016 Phase-I clinical trials in Parkinson's disease in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top